![[PRC HOME]](images/hivribbon.gif) |
|
 |
|
|
|
 |
|
|
 |
 |
|
| |
Antiretroviral Under Investigation
NRTI/NtRTI |
Code |
Drug Name |
Brand Name |
Abbreviation |
Pharmaceutical Company |
Current Status (if available) |
Further Information |
DPC-817 |
dexelvucitabine |
Reverset |
DFC |
Pharmasset/Incyte |
Phase 2B trial completed 8/05 |
pharmasset.com |
PSI5004 |
|
Racivir |
RCV |
Pharmasset |
Phase II clincal trial results anticipated furing first quarter of 2006 |
pharmasset.com |
ACH-126, 443/Beta-L-Fd4C |
elvucitabine |
|
ACH-126 |
Achillion Pharmaceuticals |
Phase II studies |
achillion.com |
MIV 310 |
alovudine |
|
|
Medivir |
Phase II studies completed |
aidsmap.com |
NcRTI-1 |
|
|
|
Tibotec |
Preclinical Studies |
retroconference.org |
DOT-Tp |
|
|
|
Decatur Corp |
Preclinical Studies |
retroconference.org |
E2-FdA |
|
|
|
Kumamoto U/Yasama Corp |
Preclinical Studies |
retroconference.org |
PSI-6130 |
|
|
|
Pharmasset/Hoffmann-La Roche |
Preclinical Studies, phase I expected in 2006 |
pharmasset.com |
AVX754 |
|
|
|
Avexa |
Phase IIB results expected mid 2006 |
avexa.com.au |
NNRTI |
|
calanolide A |
calanolide A |
|
Sarawak Medichem Pharmaceuticals |
Phase II |
sarawak-medichem.com |
BILR350BS |
|
|
|
Boehringer Ingleheim |
Preclinical Studies |
retroconference.org |
MIV150 |
|
|
|
Chiron/Medivir |
|
medivir.com |
DMP/DPC 963 |
|
|
|
Bristol-Myers Squibb |
|
aidsmap.com |
KP-1461 |
|
|
|
Koronis Pharmaceuticals |
Phase Ib safety trials underway |
koronispharma.com |
TMC-278 |
|
|
|
Tibotec |
Phase IIb ongoing |
tibotec.com |
TMC-125 |
etravirine |
|
|
Tibotec |
Phase IIb ongoing, Phase III recruiting |
tibotec.com |
GS9148 |
|
|
|
Gilead |
Preclinical Studies |
retroconference.org |
|
dioxolane thymidine |
|
DOT |
University of Georgia |
Phase I |
retroconference.org |
695634/678248 |
|
|
|
GlaxoSmithKline |
Phase I |
hivandhepatitis.org |
PROTEASE INHIBITORS |
TMC-114 |
darunavir |
|
|
Tibotec |
Phase III ongoing, Expanded access program 10/05 |
tibotec.com |
L-756, 423 |
|
|
|
Merck |
|
|
BMS-234475 |
|
|
|
Bristol-Myers Squibb |
|
|
AG1776 |
|
|
|
Agouron (purchased by Pfizer in 1999) |
|
|
DPC-681 |
|
|
|
Bristol-Myers Squibb |
|
aidsmap.com |
640385 |
brecanavir |
|
|
GlaxoSmithKline |
Current Phase II, Phase III anticipated in 2006 |
gsk.com |
SPI-256 |
|
|
|
Sequoia Pharma |
Preclinical studies |
retroconference.org |
GRL-02031 |
|
|
|
NCI |
Preclinical studies |
retroconference.org |
FUSION/ENTRY INHIBITORS |
UK-427, 857 |
maraviroc |
|
|
Pfizer |
Phase III |
aidsmap.com |
SCH-417690/SCH-D |
vicriviroc |
|
|
Schering |
Phase II |
hivandhepatitis.com |
TNX-355 |
|
|
|
Tanox, Inc |
Phase II |
tanox.com |
AMD-070 |
|
|
|
AnorMED |
Phase Ib/IIa trial initiated in 2005 |
anormed.com |
PRO 140 |
|
|
|
Progenics |
Phase Ib trial initiated in 2005 |
progenics.com |
Peptide T |
|
|
|
Advanced Immuni T, Inc. |
|
|
T1249 |
|
|
|
Trimeris |
Phase I/II trial ongoing |
trimeris.com |
TR290999, TR29144 |
|
|
|
Trimeris |
Preclinical Studies |
retroconference.org |
zinc finger nuclease |
|
|
|
Sangamo BioSci |
Preclinical Studies |
retroconference.org |
mAb004 |
|
|
|
Hum Genomic Sci |
Preclinical Studies |
retroconference.org |
AK602 |
|
|
|
Kumamoto University |
Phase I |
retroconference.org |
BMS378806 |
|
|
|
Bristol-Myers Squibb |
Phase I |
nature.com |
TAK 220 |
|
|
|
Takeda |
Phase I |
|
MATURATION INHIBITORS |
PA-457 |
|
|
|
Panacos Pharmaceuticals |
Phase II |
hivandhepatitis.com |
UK201844 |
|
|
|
Pfizer |
Preclinical Studies |
retroconference.org |
INTEGRASE INHIBITORS |
GS 9137/JTK-303 |
|
|
|
Gilead |
Phase II |
aidsmap.com |
MK 0518 |
|
|
|
Merck |
Phase II interim results presented |
aidsmap.com |
ZINC FINGER INHIBITORS |
|
Azodicarbonamide |
|
ADA |
Hubriphar |
Phase I/II preliminary results published in 2000 |
aidsmap.com |
OTHER |
|
atvogen |
Ampligen |
|
Hemispherx Biopharma, Inc |
Phase IIb ongoing |
hemispherx.net |
KD-247 |
|
|
|
Kumamoto Univ |
|
|
|
|
|
| |
|
